seekingalpha.com
Amplifon S.p.A. (AMFPF) Q4 2025 Earnings Call Transcript
Amplifon S.p.A. (AMFPF) Q4 2025 Earnings Call Transcript
AMFPFAMFPFOTC
Loading
Latest News
Loading news...
defenseworld.net
Sonic Healthcare (OTCMKTS:SKHHY) and Amplifon (OTCMKTS:AMFPF) Critical Survey
Amplifon (OTCMKTS:AMFPF - Get Free Report) and Sonic Healthcare (OTCMKTS:SKHHY - Get Free Report) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends. Analyst Recommendations This is a summary of current
defenseworld.net
Amplifon (OTCMKTS:AMFPF) vs. Eurofins Scient (OTCMKTS:ERFSF) Head to Head Analysis
Amplifon (OTCMKTS:AMFPF - Get Free Report) and Eurofins Scient (OTCMKTS:ERFSF - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation. Volatility and Risk Amplifon has a beta of 0.44,
defenseworld.net
Amplifon (OTCMKTS:AMFPF) Stock Price Up 12.7% – Here’s What Happened
Shares of Amplifon S.p.A. (OTCMKTS:AMFPF - Get Free Report) rose 12.7% on Monday. The stock traded as high as $16.49 and last traded at $16.49. Approximately 4,454 shares changed hands during mid-day trading, an increase of 1,899% from the average daily volume of 223 shares. The stock had previously closed at $14.63. Analysts Set
seekingalpha.com
Oakmark International Small Cap Strategy Q3 2025 Top Contributors And Detractors
Wynn Macau was a contributor during the quarter. The Hong Kong-based casino operator saw its stock price rise despite delivering underwhelming second-quarter 2025 results. Azimut Holdings was a contributor during the quarter. The Italian financials firm's stock price rose as it posted solid results during the period, in our view. Amplifon was a detractor during the quarter. The Italian hearing aid company's stock price plunged after first half results revealed that revenue grew more slowly than expected, and the company reduced its fiscal year guidance.
seekingalpha.com
Amplifon S.p.A. (AMFPF) Q3 2025 Earnings Call Transcript
Amplifon S.p.A. (OTCPK:AMFPF) Q3 2025 Earnings Call October 29, 2025 1:30 PM EDT Company Participants Francesca Rambaudi - Investor Relations Director Enrico Vita - CEO, MD, GM & Executive Director Gabriele Galli - Chief Financial Officer Conference Call Participants Andjela Bozinovic - BNP Paribas Exane, Research Division Hassan Al-Wakeel - Barclays Bank PLC, Research Division Anchal Verma - JPMorgan Chase & Co, Research Division Veronika Dubajova - Citigroup Inc., Research Division Domenico Ghilotti - Equita SIM S.p.A.
reuters.com
SHORT TAKE Amplifon posts Q3 profit fall, confirms 2025 guidance
Italian hearing aid group Amplifon reported a 27.7% drop in its third-quarter adjusted net profit to 19.2 million euros ($22.4 million) on Wednesday.
seekingalpha.com
Significant Research Activity Led To Six New Positions
Significant research activity at the firm led to six new positions being added to the Fund while three were exited. While the quarter's performance was disappointing, we took advantage of market opportunities to increase positions in stocks where share prices diverged from our view of intrinsic value. Alten is one of a handful of companies in this space that is considered a global tier-1 service provider, which helps them tightly embed with customers in very sticky relationships.
seekingalpha.com
Stock Picks From Seeking Alpha's August 2025 New Analysts
In August, Seeking Alpha welcomed 26 new analysts. This article introduces them and showcases some of their top picks. Analysts highlighted include The J Thesis, recommending PayPal; Ihor Pohkyton, on Keurig Dr Pepper; and David Hotea, writing about Cleveland-Cliffs—all rated as Buys. Analysts' diverse backgrounds span sectors like financials, semiconductors, and utilities, with investment strategies focusing on value and growth investing and options trading.
seekingalpha.com
Amplifon: iPhone Moment Or Contrarian Opportunity Of The Year?
Amplifon's recent weak results and macro uncertainty have led to a sharp stock sell-off, creating a contrarian buying opportunity. The company boasts a global market-leading distribution network, strong brand partnerships, and scale-driven cost advantages, supporting long-term growth. Financials remain solid with manageable debt and healthy free cash flow, despite a below-investment-grade credit rating due to sector cyclicality.
seekingalpha.com
Amplifon: The Hearing Care Giant Is Ready To Restart
Amplifon, a global leader in hearing care, has faced a 60% stock drop due to weak demand in EMEA and potential consequences of rising tariffs in the U.S. Despite recent struggles, Amplifon remains well-positioned in a growing market, with increasing demand for hearing aids expected to rise sharply by 2050. FY2024 results showed modest revenue growth but declining EBIT and Net Income; however, investments in France and USA are expected to boost profitability by 2025.
reuters.com
Italy's Amplifon posts 2024 margin below guidance, shares drop 12%
Italian hearing aid company Amplifon reported an annual core profit margin of 23.6% on Thursday, short of its revised guidance of 24%, which along with a drop in net profit sent its shares falling 12%.
seekingalpha.com
Amplifon: A Global Leader In Hearing Care Retailing, Initiate With A 'Buy'
Amplifon S.p.A. is a global leader in hearing care services with 10,000 retail locations across 26 countries, offering a wide variety of hearing aid devices and personalized healthcare services. Despite a 50% stock price drop since November 2021, Amplifon is slightly undervalued, presenting a compelling entry point for long-term investors with a fair value of €30 per share. Amplifon's customer-centric approach, extensive global network, digital innovation, and strong M&A strategy position it for sustained market leadership and high single-digit to low teens revenue growth.
businesswire.com
Amplifon Hearing Health Care Achieves HITRUST r2 Certification
MINNEAPOLIS--(BUSINESS WIRE)--Amplifon Hearing Health Care, the leading independent provider of hearing benefit solutions in the U.S., has earned certified status by HITRUST for information security for its platform and facilities. The globally recognized HITRUST r2 Certification verifies that Amplifon's Health Solutions Plus Platform and supporting IT and business processes have met demanding regulatory compliance and industry-defined requirements and is appropriately managing risk. “HITRUST c.
reuters.com
Italy's Amplifon trims margin forecast after lower Q3 profit
Italian hearing aid company Amplifon slightly lowered its annual margin guidance on Wednesday, after it posted a drop in third-quarter net profit due to increased financial expenses and higher depreciation and amortization following acquisitions.
businesswire.com
Amplifon Named One of the 200 “America's Most Loved Workplaces” by Newsweek
MINNEAPOLIS--(BUSINESS WIRE)--Amplifon, parent company of Miracle-Ear and the world leader in hearing care services and solutions, has been included in Newsweek's annual ranking of America's 200 Most Loved Workplaces®. The ranking, developed by Newsweek in partnership with Most Loved Workplaces® and the Best Practice Institute (BPI), lists the companies that employees love the most. Amplifon is the only hearing care company included in the ranking. The ranking takes into account various element.
zacks.com
New Strong Sell Stocks for September 19th
AMKR, BW and AMFPF have been added to the Zacks Rank #5 (Strong Sell) List on September 19 2024.
zacks.com
New Strong Sell Stocks for September 18th
BAMXF, BZH and CNMD have been added to the Zacks Rank #5 (Strong Sell) List on September 18 2024.
zacks.com
New Strong Sell Stocks for August 28th
TECH, AMFPF and B have been added to the Zacks Rank #5 (Strong Sell) List on August 28, 2024.
zacks.com
New Strong Sell Stocks for August 9th
AIQUY, AMFPF and ARCO have been added to the Zacks Rank #5 (Strong Sell) List on August 9, 2024.